Express News | Morgan Stanley: Raised the Target Price for Gilead Sciences from $87 to $113, and upgraded the rating from "Neutral" to "Shareholding."

Breakings16:15

Gilead Sciences cooperates with LEO Pharma to develop projects for inflammatory diseases.

Gelonghui reported on January 13 that Gilead Sciences announced last Saturday that it has reached a collaboration with Denmark's LEO Pharma to develop a project for patients with inflammatory diseases. LEO Pharma will be eligible to receive up to $1.7 billion in payments, including a $0.25 billion upfront payment from Gilead. In return, Gilead will have the rights to develop, manufacture, and commercialize the small molecule oral STAT6 project globally. The statement noted that preclinical studies targeting STAT6 have shown potential in treating a wide range of inflammatory diseases, such as atopic dermatitis, asthma, and COPD. This Trade is expected to benefit Gilead.

Gelonghui Finance10:01

Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?

Seeking AlphaJan 12 04:06

Gilead in Pact for Anti-inflammatory Drugs in a Deal Worth up to $1.7B

Seeking AlphaJan 12 00:40

Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105

Futu NewsJan 12 00:32 · Ratings

Express News | Gilead has reached a collaboration with Leo Pharma.

BreakingsJan 12 00:21